Blueprint Medicines Corporation

BPMC

Find Out if You Qualify for a Financial Reward by filling out the form below.

Blueprint Medicines Corporation Form












Class Action Lawsuit List does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Blueprint announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) on August 17, 2022. The Company disclosed that the absolute improvement in the symptom score fell from 19.7 in the first part of the trial to 15.6 in part 2. Following this news, shares of Blueprint dropped over 10% on the same day. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Active Cases

Ticker Symbol Company Name Join Deadline Join
NSSC Napco Security Technologies, Inc. June 24, 2025 Join
NSSC Napco Security Technologies, Inc. June 24, 2025 Join
CODI Compass Group Diversified Holdings, LLC July 08, 2025 Join
IOVA Iovance Biotherapeutics, Inc. July 14, 2025 Join
OGN Organon & Co. July 22, 2025 Join
VSTS Vestis Corporation August 08, 2025 Join
RCKT Rocket Pharmaceuticals, Inc. August 11, 2025 Join